Tear film lipid layer stability (TFLL stability)

Tear film lipid layer stability refers not to a single molecule or receptor but rather to the physical and functional integrity of the outermost component of the precorneal tear film. This thin, complex mixture—primarily composed of meibomian gland-derived lipids—serves several essential roles in ocular health. It stabilizes the air/tear interface on the eye’s surface, retards evaporation from underlying aqueous layers, provides a smooth optical interface for vision, and acts as an initial barrier against microbial invasion through its detergent-like properties[1][2]. Disruption in this layer’s composition or structure leads directly to increased evaporative loss from tears—a hallmark feature in dry eye syndromes—and is most commonly associated with meibomian gland dysfunction. While drugs such as artificial tears containing lipids are formulated specifically for patients with instability in this system[4], “tear film lipid layer stability” itself is not a discrete molecular target like an enzyme or receptor; rather it describes an emergent property resulting from interactions among many molecules including wax esters, cholesterol esters, triglycerides, phospholipids, proteins such as lipocalin—and their dynamic behavior during blinking cycles[1][3]. Thus it should not be classified as a canonical therapeutic target. In summary: “Tear film lipid layer stability” describes a physiological property critical for ocular health but does not correspond to any single molecule or druggable biological entity; therefore it is not considered a canonical therapeutic target.

Other names

Tear film lipid layerTFLLtear film stabilitytear lipid layer stability

Supplementation or stabilization of the tear film by providing exogenous lipids to restore barrier function and reduce evaporation